drugset
drugset / Trial / NCT03464227

A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects

NCT03464227 ↗

Phase 1 Completed 52 enrolled UCB Biopharma S.P.R.L.
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of the study is to evaluate the safety and tolerability of single ascending doses of UCB0107 administered by intravenous (iv) infusion in healthy male subjects.

Timeline

Start
2018-02-16
Primary completion
2018-12-01
Completion
2018-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject bepranemab Monoclonal antibody — Intravenous

Indications

No indication recorded.